EGFR mutants are not a monolithic entity. In fact EGFR mutational status is heterogeneous and EGFR mutated cancers can be Dr Jekyll or Mr Hyde #AACR24 Marina Garassino

Cannot wait for the plenary session today at #ASCO24 ASCO! Laura Ph 3: Osimertinib vs Placebo for unresectable Stage III NSCLC after conc. CRT. ➡️24 months PFS of 39.1 vs 5.6 mo ➡️≥Grade 3 AEs in 35% vs 12% ➡️ AEs --> discontinuation in 13% vs 5% ➡️81% Osi at progression

Two lungnerds excited for plenary session #ASCO24 Arthi Sridhar

More innovation in SCLC! 🫁 ADRIATIC 🌊 shows an improvement in median OS from 33.4 to 55.9 months w/ consolidation durvalumab after CRT! 🙌 Interesting to note LS-SCLC is enriched for the inflamed subtype. Looking forward to trials tailoring treatment to specific subtypes.

Welcome to the #ASCO24 #FlorezLab lunch!!! Great people, finger-licking cuisine, incredible connections - the best place to be‼️ 🍽️💡 #Networkinglunch #florezlabeverything ASCO

Ladies who lung together #ASCO24 #lcsm IASLC ASCO Hem-Onc Fellows Network Hematology & Oncology Women Physicians Group—HOWPG

#ASCO24 environmental signatures in non-smoking lung cancer in Asia

Management of pregnancy w/ 🫁ca 🚫 1st trimester ✅Dose according to actual body weight ✅Maintain dose intensity 🚫increase/decrease the dose 🚫chemotherapy @ 35-37 of gestation ✅minimum 3-week interval between the last cycle➡️delivery 🚫avoid IO in 2/3 trim 👀🫁-Matteo Lambertini, MD PhD

Osimertinib use associated with nutritional deficiencies ❗️Significant deficiencies of Vit B, Vit D, Iron, Vit B12 ❓May reflect GI side effects of drug 🤔 Should screen for these during Osimertinib treatment: quick and cheap to do #ASCO24 #LCSM

A few more highlights from Mayo fellows at #ASCO24! Arthi Sridhar @Aditisinghlove

Can always trust Jennifer A. Marks, MD to summarize a lung session if you happen to miss it. #ASCO24

Diets | New England Journal of Medicine nejm.org/doi/full/10.10… Excellent paper on diets. Robust evidence for Mediterranean diet benefits🫒

Make Way for the Celtics. 💚

🫁 Lung Cancer - ICIs data 🫁 🌟 Summary of 5-year (long follow-up) data 🌟 NSCLC (NSQ & SQ) #Immunotherapy #Lungcancer #longfollowup #LCSM

Do we need to do cardiac monitoring for all patients on Osimertinib? Congrats to Dr Francisco Martinez, recent KPSF fellowship graduate’s poster at #wclc2024 Bottom line: >800 pts, 3700 ECHOs, only 10 Osi HF events Higher in a fib, CHF hx pts Kaiser Permanente Research NorCal Raymond Liu lori sakoda

Hot off the press, Alliance CABINET! Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs. The primary endpoint, PFS, was significantly better in the cabo arm than placebo. Alliance for Clinical Trials in Oncology nejm.org/doi/full/10.10…

esmo.org/guidelines/gui…

Report on NGS in squamous NSCLC Lung Cancer Journal from Dr. Joshua Reuss et al. Detected actionable genomic alterations in 22.2% of patients with squamous NSCLC and no history of smoking including #EGFR and #MET. In those with prior smoking, AGAs in 2.4%. lungcancerjournal.info/article/S0169-…

Does immunotherapy in #SCLC delay brain metastases? Retrospective report Lung Cancer Journal on 550 pts show pts treated with atezolizumab + carbo/etop longer time to intracranial progression: 24.4 vs 14.3m and if no PCI: 27.2 vs 15.2m. Improved PFS and OS. lungcancerjournal.info/article/S0169-…

A082101 led Aaron Mansfield of Mayo Clinic evaluates the safety & effectiveness of immunotherapy before surgery for #mesothelioma. #Immunotherapy helps the body’s immune system fight cancer. Learn more: bit.ly/Alliance-A0821… @thenci #nctn